Cytogenetic studies in @entity1358 @entity1 receiving low-dose recombinant XXXX -based immunotherapy.

@entity1 @entity54336 @entity981 @entity5 @entity1358 @entity5041 @entity1199
A variety of cytogenetic aberrations have been reported in sporadic and @entity1358 . Rearrangements of the short arm of chromosome 3 (3p), trisomy 17, and nuclear hyperdiploidy have been reported to be common clonal chromosome changes. We analyzed a total of ten @entity5 -derived cell lines from @entity1 who underwent nephrectomy for @entity1358 employing conventional cytogenetics. All @entity1 received an immunomodulatory therapy based on recombinant @entity1199 ( @entity5041 ). @entity5 stage and grade, histo- and cytopathology, and @entity1 ' response to immunotherapy were assessed and correlated statistically to rearrangement of 3p, trisomy 17, and nuclear hyperdiploidy. @entity54336 as clonal aberration could be revealed only in @entity1358 , whereas @entity5 with compact or tubulopapillary growth pattern lacked this abnormality (p < 0.002). One of 3 @entity1 with diploid or near-diploid karyotype (< or = 49 chromosomes) achieved a partial remission while two presented with stable disease after immunotherapy. In contrast, all 6 @entity1 with @entity5 progression upon @entity5041 -based immunotherapy revealed @entity981 (> 49 chromosomes) karyotypes. The correlation between hyperdiploidy and @entity5 progression was found to be statistically significant (p < 0.029). Interestingly, the only @entity1 achieving an objective @entity5 remission after immunotherapy presented with a normal diploid karyotype. Our findings suggest @entity5 hyperdiploidy as an adverse prognostic factor in @entity1358 @entity1 receiving @entity5041 -based immunotherapy.
